Therefore, further preclinical investigations are needed evaluating both the anti-cancer effect and the cardioprotective potential of the adjuvant anti-IL-1ß drug via the use of translational models, i.e. tumor-bearing mice treated with the anti-cancer drug. This evidence concerns the gene IL1B and neoplasm.